Generating a recombinant phosphothreonine-binding domain for a phosphopeptide of the human transcription factor, c-Myc

New Biotechnology
Leon A VenegasBrian K Kay

Abstract

Transcription factor c-Myc is an oncoprotein that is regulated at the post-translational level through phosphorylation of two conserved residues, Serine 62 (Ser62) and Threonine 58 (Thr58). A highly specific tool capable of recognizing Myc via pThr58 is needed to monitor activation and localization. Through phage display, we have isolated 10 engineered Forkhead-associated (FHA) domains that selectively bind to a phosphothreonine (pThr)-containing peptide (53-FELLPpTPPLSPS-64) segment of human c-Myc. One domain variant was observed to bind to the Myc-pThr58 peptide with a KD value of 800 nM and had >1000-fold discrimination between the phosphorylated and non-phosphorylated peptide. The crystal structure of the engineered FHA Myc-pThr-binding domain (Myc-pTBD) was solved in complex with its cognate ligand. The Myc-pTBD was observed to be structurally similar to the yeast Rad9 FHA1 domain, except that its β4-β5 and β10-β11 loops form a hydrophobic pocket to facilitate the interaction between the domain and the peptide ligand. The Myc-pTBD's specificity for its cognate ligand was demonstrated to be on a par with 3 commercial polyclonal antibodies, suggesting that this recombinant reagent is a viable alternative to antibodies for mo...Continue Reading

References

Jun 23, 1999·Oncogene·C E NesbitE V Prochownik
Mar 26, 2002·FEBS Letters·Daniel Durocher, Stephen P Jackson
Dec 31, 2003·Methods in Enzymology·Martyn D WinnMiroslav Z Papiz
Dec 29, 2006·The Journal of Biological Chemistry·Julienne R Escamilla-Powers, Rosalie C Sears
Jul 25, 2007·The Journal of Experimental Medicine·Jennifer O'NeilA Thomas Look
Apr 15, 2008·Journal of Neuroscience Methods·Natasha L GrimseyE Scott Graham
Apr 19, 2008·Nature Reviews. Immunology·Iannis AifantisSilvia Buonamici
Oct 16, 2008·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·John R Couchman
Nov 8, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Brian C JensenPaul C Simpson
Nov 26, 2008·RNA·Doreen WeidensdorferStefan Hüttelmaier
Nov 26, 2008·Nature Reviews. Cancer·Natalie Meyer, Linda Z Penn
Feb 10, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Wisuit PradidarcheepWouter H Lamers
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Jan 27, 2011·Cancer Research·Xiaoyan WangRosalie C Sears
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Martyn D WinnKeith S Wilson
Jul 31, 2012·Proceedings of the National Academy of Sciences of the United States of America·Lutz KummerAndreas Plückthun
Jan 2, 2013·Methods : a Companion to Methods in Enzymology·Kritika Pershad, Brian K Kay
Jun 26, 2013·Chemistry & Biology·Lutz KummerAndreas Plückthun
May 29, 2014·Naunyn-Schmiedeberg's Archives of Pharmacology·Tobias BöhmerAdrian Gericke
Nov 22, 2014·Cell Death and Differentiation·S LiP Wang
Oct 21, 2015·Biotechnology Advances·Katherine GroffAmy J Clippinger

❮ Previous
Next ❯

Citations

Oct 26, 2018·International Journal of Molecular Sciences·Jennifer E McGinnisBrian K Kay
May 13, 2021·Science Signaling·Rashida Abdul-GaniyuDavid E Stone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.